International Space Medicine Summit 2013 -- Panel II: Planning for Long-duration Missions (Rus)
May 17, 2013 Physicians and biomedical scientists gather to discuss space medicine research at this annual conference organized by the Baker Institute and Ba...
By: BakerInstitute
Read more:
Three Take Home Nobel Medicine Prize
The winners are in. (SOUNDBITE) (English) SECRETARY OF THE NOBEL COMMITTEE FOR PHYSIOLOGY OR MEDICINE, GORAN K. HANSSON, READING ANNOUNCEMENT IN FIVE LANGUAG...
By: NTDTV
View post:
International Space Medicine Summit 2013 -- Panel III: Maximizing Scientific Return (Rus)
May 17, 2013 Physicians and biomedical scientists gather to discuss space medicine research at this annual conference organized by the Baker Institute and Ba...
By: BakerInstitute
Read the original:
International Space Medicine Summit 2013 -- Panel III: Maximizing Scientific Return (Rus) - Video
Two Americans One German Win Nobel Medicine Prize
The three scientists earned the award for their research into how things like proteins and molecules move within cells. Full story: The winners are in. [Gora...
By: NTDTV
Read this article:
NEW YORK, NY--(Marketwired - Oct 11, 2013) - In 2003 Michael Caridi was awarded with the prestigious honorary doctorate for his contribution and support of Podiatric medicine and the city of Harlem. Michael Caridi today continues his efforts to see Harlem's economy grow.
"I'm very proud to have received this award from such an esteemed college which is one of the oldest podiatric colleges in the country," said Michel Caridi. He went on to say, "Supporting academic institutions like this is crucial for future of our youth and our country. It helps move our country forward, and keeps the door open to obtain the American Dream. God bless America."
About College of Podiatric Medicine:
Located in the City of New York, the College had its first home at 125th Street and rapidly outgrew its quarters. Three successive moves culminated in the erection in 1927 of the present College building dedicated to podiatric medical education and clinical training.
Completed in 1978, the new facility, the Foot Center of New York, provides clinical services to the community and continues to be affiliated with the College. The largest center of its kind, the Foot Center of New York ministers to a wide and diverse patient load in more than 25,000 patient visits annually.
The College has recently completed a series of renovations that have brought its classrooms and labs to the leading edge of medical education technology.A new Anatomy Lab and a new Clinical Skills Lab, as well as fully renovated classrooms, computer rooms, study areas and other College facilities, enable students to work in an environment optimized for learning and for study.
NYCPM is affiliated with a number of leading medical institutions in the New York City area, including the Columbia University College of Physicians & Surgeons, Harlem Hospital Center, Lincoln Medical & Mental Health Center, Long Island College Hospital, Metropolitan Hospital Center, Nassau University Medical Center, the New York-Presbyterian Healthcare System, and Parker Jewish Institute for Health Care and Rehabilitation.These affiliations provide additional outstanding educational and clinical opportunities for NYCPM's students.
About Michael Caridi Michael Caridi was born in Brooklyn and raised in Catskill, NY. He currently resides in Greenwich, Connecticut and has offices in Mid-town Manhattan, New York, NY. He is married and has four children. A graduate of St. John's University, Michael Caridi obtained a Bachelor of Science degree in Accounting and Business Administration.Michael Caridi's business endeavors span various industries. He is currently Managing Director of Seahawk Capital Partners which specializes in business development & consulting, mainly in the BioTech Industry.Michael Caridi is Chairman of MAJIC Development Group LLC, and has been involved in several significant development projects, as well as construction for many Fortune 500 clients and retailers. Among Michael Caridi's most notable achievements are: lease acquisition, obtaining the air rights, and negotiation of the sale of Harlem Park, a mixeduse project in Harlem, NYC; the lease acquisition, financing, gutting and fullscale rehab of the 600room Holiday Inn Hotel on West 57th Street in Manhattan; the acquisition, financing and construction of a 204unit, $70 million condominium and rental complex in Palisades Park, New Jersey; and the acquisition, renovation and sale of 96 coop apartments in Long Beach, NY.Other recent projects include involvement in an Italian Cosmetic Wipe company, an ecofriendly plastics and electronics company that had products in 70,000 retail stores, and a diverse mix of independent business ventures including residential and commercial propertyownership, restaurant owner, mortgage banking, ship salvaging and dismantling, hotel ownership and development, security services, magazine publishing, and alcohol/nonalcoholic import and export.
Michael Caridi's philanthropic efforts have rivaled those of his business successes. In the past he has served on the Board of Directors of the Coalition of Italian American Associations; the Republican Leadership Council; The Forum Club; The National Ethnic and Charitable Organization; and The Italo American Foundation. Michael Caridi is a proud member of the Lumen Institute, and supporter of the New York City Police Foundation and C.O.R. E. (Congress of Racial Equality).
Michael Caridi Awards and Honors:
Here is the original post:
Michael Caridi Awarded Honorary Doctorate From College of Podiatric Medicine
SINGAPORE AND TORONTO, ONTARIO--(Marketwired - Oct 11, 2013) - 360ip and the Canadian Centre for Commercialization of Regenerative Medicine (CCRM) are signing a collaboration agreement to work together in a variety of areas, including developing a fund to invest in best-in-class regenerative medicine (RM) technologies and companies in Asia, Europe and North America.
"360ip has expertise in identifying, commercializing and monetizing intellectual property [IP] worldwide with a particular focus in Asia," explains Asashi Fujimori, SVP of 360ip and Representative Director of 360ip JAPAN. "CCRM has built up an excellent network of leading academic and industry partners in the RM field, and combined with our strengths and contacts, we expect great things to come from this partnership."
"It benefits Canada if CCRM is sourcing best-in-class RM IP from around the world and this affiliation opens the doors for CCRM to do just that," says Michael May, CEO of CCRM. "This fund is an exciting undertaking that will be good for the global community. I'm very pleased that CCRM's value has been recognized internationally and we look forward to collaborating with 360ip, a commercialization leader in the Asian market."
360ip JAPAN, a 360ip affiliate, provides technology commercialization, investment and fund management expertise across a variety of industries with a particular emphasis on the life sciences. 360ip JAPAN was recently selected by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) to serve as a Project Promoter under the STart-ups from Advanced Research and Technology (START) Program. 360ip JAPAN's area of focus for this program is regenerative medicine and it will work closely with CCRM to identify marketable IP.
Representatives from 360ip and CCRM are currently attending Bio Japan 2013 in Yokohama, Japan, from October 9-11 http://www.ics-expo.jp/biojapan/seminar_schedule.html. Dr. Allison Brown, Director of Commercialization for CCRM, presented "Overview of Canada's Public-Private Partnership in Commercialization of Stem Cell Research - A Focus on Stem Cell-based Predictive Drug Screening" on Oct. 9th. For a copy of her presentation, contact CCRM.
About 360ip Pte Ltd ("360ip")
360ip is a global technology commercialization, investment and fund management company, headquartered in Singapore, with teams based throughout Asia and North America. 360ip includes an experienced group of operational, technical and financial professionals with a strong track record in technology commercialization and investment in high-growth companies.
360ip was jointly established by Battelle Memorial Institute ("Battelle"), the world's largest nonprofit R&D and commercialization organization, and Battelle Ventures, the venture capital firm affiliated with Battelle. Battelle, which began operations in 1929, generates more than US$6.0 billion in consolidated annual revenue, oversees more than 22,000 employees worldwide and has extensive life science-related capabilities and facilities. Battelle Ventures - whose sole limited partner is Battelle - and its affiliate fund, Innovation Valley Partners, have a combined US$255 million under management. Development Bank of Japan is also a shareholder of 360ip, and the companies have entered into a strategic collaboration in Japan.
About the Centre for Commercialization of Regenerative Medicine (CCRM)
CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011. CCRM is hosted by the University of Toronto.
Read the original post:
360ip and CCRM Join Forces to Source Best IP in Regenerative Medicine
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/g6wsxm/personalized) has announced the addition of the "Personalized Medicine Partnering Terms and Agreements" report to their offering.
This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a review of the leading pharmacogenomic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 6 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain.
Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus.
Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus.
Read the original:
American Journal of Medicine: Higher gun ownership equals higher gun violence
Ladd Everitt: Gun violence in the US is off the charts compared to other countries. See more videos: http://therealnews.com.
By: TheRealNews
More:
American Journal of Medicine: Higher gun ownership equals higher gun violence - Video
Extended Interview with Thompson Brothers on Lacrosse, the Medicine Game, and their Sticks
We enjoyed talking to these guys so much we thought you should see the full interview. Extended Interview with Thompson Brothers on Lacrosse, the Medicine Ga...
By: Stylin Strings
View original post here:
Extended Interview with Thompson Brothers on Lacrosse, the Medicine Game, and their Sticks - Video
Welcome to Apple Medicine!
Welcome to Apple Medicine!
By: Betsy Reiling
More:
Interview: 2013 Nobel Prize in Physiology or Medicine
An interview was held with Professor Juleen Zierath, Chairman of the Nobel Committee for Physiology or Medicine following the announcement. The interviewer i...
By: Nobel Prize
Read the original:
Interview: 2013 Nobel Prize in Physiology or Medicine - Video
Get to know a Bariatric Medicine Physician at VHA
Get to know a bariatric medicine physician at VHA as she describes why her work is vital to the well-being of our Veterans. You, too, can make a difference a...
By: VeteransHealthAdmin
Read the original post:
Americans Win Nobel Prize in Medicine
Two Americans and a German-American won the Nobel Prize in medicine on Monday for discovering how key substances are transported within cells, a process invo...
By: AssociatedPress
See the article here:
Medicine Hat Cubs vs Red Deer Vipers - Oct 5, 2013
Please subscribe to enable the Cubs to use youtubes Live broadcasting feature. We need 100 subscribers. Cubs Hockey - Exciting home game at the Kinplex. Cubs...
By: mhcubs
Read the original:
Roni Zeiger - Stanford Medicine X 2013 - Joyce Ho in Conversation with Roni Zeiger
Stanford Medicine X host Joyce Ho in conversation with Roni Zeiger on Smartpatients.
By: StanfordMedicineX
Read the original here:
Roni Zeiger - Stanford Medicine X 2013 - Joyce Ho in Conversation with Roni Zeiger - Video
McDougall Chiropractic Medicine, ESL Medical Terminologylarge]
By: Hello Channel
More:
McDougall Chiropractic Medicine, ESL Medical Terminologylarge] - Video
Public release date: 9-Oct-2013 [ | E-mail | Share ]
Contact: Gina DiGravio gina.digravio@bmc.org 617-638-8480 Boston University Medical Center
(Boston) - Investigators at Boston University School of Medicine (BUSM) have identified that lack of time and a paucity of trained faculty are perceived as the most significant barriers to incorporating complementary and alternative medicine (CAM) and integrative medicine (IM) training into family medicine residency curricula and training programs.
The study results, which are published online in Explore: The Journal of Science and Healing, were collected using data from an online survey completed by 212 national residency program directors. The study was led by Paula Gardiner, MD, MPH, assistant professor of family medicine at BUSM and assistant director of integrative medicine at Boston Medical Center, and colleagues from the department of Family Medicine.
"This is a part of medicine that has significant impact on patient care," said Gardiner. "We need to minimize barriers to implementing CAM/IM curricula in order to address these competencies and promote a larger focus on patient centered care."
According to the current study a majority of family medicine residency program directors felt that CAM and IM were an important part of resident training and, of those, a majority was aware of these recommended competencies. However, a majority of directors also did not have specific learning goals around CAM and IM in their residency programs. Of those directors aware of the competencies, a minority had an adequate evaluation of CAM or IM in their program.
The survey respondents identified "strong" CAM/IM programs as those that incorporated at least one of the following modes of exposing residents to CAM or IM: didactics, clinical rotations or electives. "Weak" programs incorporated none of these modalities. Didactics were the most commonly employed techniques of the strong programs. There were significant differences between the strong and weak programs in perceived access to experts in CAM or IM and faculty training in these modalities.
The study was conducted via an online survey and consisted of six questions on CAM and IM with a focus on awareness, competencies, attitudes toward curricula, barriers to implementation and management techniques.
Given the use of CAM and IM modalities by patients and practicing physicians future directions should include raising awareness around the proposed competencies and identifying solutions to minimize the barriers to incorporating these competencies in residency training programs.
###
See more here:
BUSM identifies barriers to implementing complimentary medicine curricula into residency
Oct. 9, 2013 Investigators at Boston University School of Medicine (BUSM) have identified that lack of time and a paucity of trained faculty are perceived as the most significant barriers to incorporating complementary and alternative medicine (CAM) and integrative medicine (IM) training into family medicine residency curricula and training programs.
The study results, which are published online in Explore: The Journal of Science and Healing, were collected using data from an online survey completed by 212 national residency program directors. The study was led by Paula Gardiner, MD, MPH, assistant professor of family medicine at BUSM and assistant director of integrative medicine at Boston Medical Center, and colleagues from the department of Family Medicine.
"This is a part of medicine that has significant impact on patient care," said Gardiner. "We need to minimize barriers to implementing CAM/IM curricula in order to address these competencies and promote a larger focus on patient centered care."
According to the current study a majority of family medicine residency program directors felt that CAM and IM were an important part of resident training and, of those, a majority was aware of these recommended competencies. However, a majority of directors also did not have specific learning goals around CAM and IM in their residency programs. Of those directors aware of the competencies, a minority had an adequate evaluation of CAM or IM in their program.
The survey respondents identified "strong" CAM/IM programs as those that incorporated at least one of the following modes of exposing residents to CAM or IM: didactics, clinical rotations or electives. "Weak" programs incorporated none of these modalities. Didactics were the most commonly employed techniques of the strong programs. There were significant differences between the strong and weak programs in perceived access to experts in CAM or IM and faculty training in these modalities.
The study was conducted via an online survey and consisted of six questions on CAM and IM with a focus on awareness, competencies, attitudes toward curricula, barriers to implementation and management techniques.
Given the use of CAM and IM modalities by patients and practicing physicians future directions should include raising awareness around the proposed competencies and identifying solutions to minimize the barriers to incorporating these competencies in residency training programs.
Go here to see the original:
Barriers to implementing complimentary medicine into MD residency
Newswise PHILADELPHIA D. Gary Gilliland, MD, PhD, has been named the inaugural Vice Dean and Vice President for Precision Medicine, a newly created role to position Penn Medicine as the nations top leader in the delivery of individualized medicine.
Dr. Gilliland, a cancer genetics expert and pioneer in the development of targeted therapies, will synthesize Penn Medicines research and clinical care initiatives across all disciplines to create a national model for the delivery of precise, personalized medicine to patients with diseases of all kinds. He will work with the institutions top leaders in cancer, heart and vascular medicine, neurosciences, genetics, pathology, and many other specialties.
We are proud to be among the first institutions in the country to create a position to oversee the tremendous opportunities and challenges that face us as our physicians and scientists work to hone the promise of the burgeoning and exciting field of precision medicine, says J. Larry Jameson, MD, PhD, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the Perelman School of Medicine. Dr. Gillilands experience as a leader in both academic medicine and the pharmaceutical industry will help Penn Medicine forge a roadmap for the most effective and efficient ways to conduct research and deliver care in this new field.
The establishment of the new role builds on such existing Penn Medicine efforts as the Institute for Translational Medicine and Therapeutics and the newly launched Center for Personalized Diagnostics.
Penn Medicine already has a strong base in this new field, and Dr. Gillilands background and accomplishments will provide experienced leadership to take us to the next level of excellence, says Ralph W. Muller, Chief Executive Officer of the University of Pennsylvania Health System. No matter what its called precision medicine, personalized medicine, or individualized medicine this extremely promising approach will better equip physicians to match the most effective treatment to each patients specific disease.
Gilliland joins Penn Medicine from Merck, where he was recruited in 2009 as Senior Vice President of Merck Research Laboratories and Oncology Franchise Head, following a long career at Harvard Medical School. At Merck, he was responsible for end-to-end research and development of its Global Oncology Programs. He oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials, and managed all preclinical and clinical oncology licensing activities.
Prior to joining Merck, Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute. He saw patients at numerous top Boston hospitals, serving as an attending physician in the Bone Marrow Transplant Service of Childrens Hospital; attending physician in medical oncology at Dana-Farber Cancer Institute; and senior attending physician at Brigham and Womens Hospital.
As an investigator studying hematologic malignancies, Gilliland made seminal discoveries that have contributed to the understanding of the genetic basis of leukemias and other cancers that affect the blood and bone marrow. He has worked to help apply these findings into the development of new investigational cancer treatments, including molecularly targeted therapies, and has advanced this research into all phases of clinical development.
His work has earned him numerous honors, including the William Dameshek Prize from the American Society of Hematology, the Emil J. Freireich Award from the MD Anderson Cancer Center, and the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation. He is an elected member of the America Society for Clinical Investigation and the American Association of Physicians.
He received his Ph.D. in Microbiology from the University of California, Los Angeles, and his M.D. from the University of California, San Francisco. He completed his internship and residency, including serving as Chief Medical Resident, at Brigham and Women's Hospital, Harvard Medical School. He completed his Hematology and Medical Oncology training at the Brigham and Womens Hospital and the Dana-Farber Cancer Institute, respectively.
View original post here:
Nahko and Medicine for the People 02
By: alohamrhand
Excerpt from: